[blindza] Re: Fw: Microchips in the Eye
- From: "Robin Barker" <robinb@xxxxxxxxxx>
- To: <blindza@xxxxxxxxxxxxx>
- Date: Thu, 3 Mar 2011 07:14:29 +0200
Hi Jacob,
Thanks for the article. Interesting and looking forward to the advances.
Robin
-----Original Message-----
From: blindza-bounce@xxxxxxxxxxxxx [mailto:blindza-bounce@xxxxxxxxxxxxx] On
Behalf Of Jacob Kruger
Sent: Thursday, March 03, 2011 6:32 AM
To: NAPSA Blind
Cc: BlindZA
Subject: [blindza] Fw: Microchips in the Eye
----- Original Message -----
Microchips in the Eye.
Electronic retinal implants are gaining popularity as research into the
technology continues to show improvements for patients.
About 30 research groups worldwide are currently working on an electronic
retinal implant. Retina Implant AG, a company in Reutlingen, Germany, has
conducted a successful clinical pilot study demonstrating that the technique of
subretinal stimulation permits visual recognition of patterns and letters of
the alphabet. This study confirms electronic retinal implants can give very
useful visual perceptions to the blind (See three videos regarding Retina AG
study results and demonstrations
http://www.mddionline.com/video-vault-retina-implant-ag-electronic-microchip
).
Hereditary retinal degeneration (retinitis pigmentosa) results in a progressive
loss of photoreceptors and in most cases leads gradually to a complete loss of
vision. More than 100,000 people in the United States and an estimated three
million people worldwide suffer from various forms of this disease. Although
drugs are currently under development, there is as yet no therapy for this
ailment. However, many of those affected may soon be able to recover a certain
degree of vision by means of an implanted camera chip.
In the normal eye, incident light passes through the transparent tissue of the
retina and falls on some 120 million rods and six million cones at the fundus
of the eye. The light is converted in a multiple-stage process into electrical
signals. These signals undergo preliminary processing in the underlying layers
of bipolar, horizontal, and amacrine cells and are then passed on to the
ganglion cells. For their part, the axons of the ganglion cells communicate
with the optic nerve, which forwards the information gained thus far to the
visual cortex (i.e., visual center) of the brain.
Subretinal Implants.
Diseases like retinitis pigmentosa (RP) are distinguished by the fact that a
large part of the retina remains functional even after loss of sight.
Although
the rods and cones that normally convert light into nerve signals are destroyed
by this disease, most of the retinal nerve tissue, which has the task of
pre-processing information on its way to the brain, remains intact. In other
words, the visual apparatus is functional; it just lacks input. Based on this
concept, Eberhart Zrenner at the University Eye Clinic of Tübingen has
developed a subretinal implant in cooperation with that university's Institute
of Natural Science and Medicine (NMI).
For the university's implant, natural optical stimulus is simply replaced by
pulsed, light-dependent electrical stimuli, resulting in the perception of
phosphenes (artificially triggered light phenomena). Because the electrical
excitation invariably involves a number of cells, the patients cannot visualize
objects sharply, but are nevertheless able to locate light sources and localize
physical objects.
The implant is located subretinally, i.e. behind the retina. From an anatomical
point of view, it exactly replaces the photoreceptors that have been lost (see
Figure 1). From the viewpoint of signal processing, this is an all-important
advantage; the implant's subretinal excitation exploits the full range of
neuronal circuitry in the retina along the way to the optic nerve. The
electrical signal is triggered at the point of brightness, and the stimulation
strength corresponds to the intensity of the incident light. The optical image
is thus exactly replaced by an electrical pattern of excitation.
The retinal implant consists of a silicon chip about 3 × 3 mm in size and 70-µm
thick, with 1500 individual pixels. Each of these pixel cells contains a
light-sensitive photodiode, a logarithmic differential amplifier, and a 50 ×
50-µm iridium electrode into which the electrical stimuli at the retina are
guided. The circuitry was developed in collaboration with the IMS in Stuttgart
and is made by applying 0.8-µm CMOS technology.2 The result is a pure analog
chip, with the advantage that its power consumption is very low (maximum 10
mW), and the heat passed on to the retina by electrical power from the chip
remains below 0.5 K. The microchip is positioned on a thin, highly flexible
circuit board of polyimide with gold circuits that transmit power and control
signals (See Figure 2). The very fine polyimide strip is connected in turn to a
thin, coiled cable through which the electricity of the chip is supplied. This
elastic cable passes through the orbital cavity to the bone of the temple and
from there to a point behind the ear, where it is connected to an inductive
power supply unit in a ceramic housing. The electrical energy is received
inductively from the outside through a second coil that is located on the skin.
Permanent magnets in the two coils ensure close contact.
All of the components must of course be biocompatible-that is, well tolerated
by the body-and must possess long-term stability. This is an enormous
technological challenge that requires, among other things, the use and
combination of new materials. The components must be provided with a
hermetically sealed protective layer at the point of contact with the
surrounding tissue. They must undergo numerous tests to demonstrate the
device's ability to withstand the corrosive environment within the body. An
especially critical point is that the presence of electrical voltage can
greatly accelerate the corrosion process. The selection of materials and the
manner in which they are processed is critical.
Above all, the electrodes and their contact points on the chip are of decisive
importance. The useable electrode surface must be as small as possible but also
offer as large a surface as possible to ensure good contact with the retina.
For
this reason, the electrodes are manufactured of fractal iridium, whereby the
materials permit a higher transmission of charges.
Optimal visual perception is present when pulse durations are around 1
microsecond and the charge amounts to 2-5 nC per pixel. This corresponds to a
voltage of up to 2 V. The repetition rate of excitation is normally 5-7 Hz,
because higher rates would result in overstimulation of the retina. The
patient's visual perception therefore flickers somewhat.
Clinical Studies and Results.
During a clinical pilot study at the University Eye Clinic in Tübingen, the
retinal implant was first tested over a period of up to four months in 11
patients. The development of a new type of surgical procedure was given high
priority in collaboration with the University Eye Clinic in Regensburg, Germany.
It involves creating a small access opening through the external sclera of the
eye. After removal of the vitreous, the retina is lifted up from its underlying
support layer so that the flexible film with the chip can be advanced under the
retina to the vicinity of the macula. This is the point at which density of the
nerve cells is greatest and can be expected to result in the most effective
stimulation. Following exact positioning, the small window through the sclera
is again closed, thus attaching the film securely in the globe of the eye so
that the chip can assume a stable position and is not subjected to tension due
to movements of the eye.
It was already possible to conduct initial tests with the patients only one
week after implantation. The majority of patients recognized not only
horizontal and vertical lines but also the direction in which electrodes were
activated one after another and simple geometric patterns. However, the
threshold value for triggering a stimulus varied widely in the different
patients. In some cases, it was possible to trigger a phosphene with individual
electrodes and a charge transfer of only a few nanocoulombs. However, many of
the patients experienced visual perception only when several.
adjacent electrodes were stimulated simultaneously.3 The causes of these
patient-specific threshold values may be both the position of the electrodes
relative to the macula and the distance between the electrodes and the bipolar
cells in the retina.
Most of the patients reported blurred visual perception. Many were able to
distinguish light sources or bright objects against a dark background. As the
ability to recognize objects grew in each patient, it became possible to
continuously optimize the stimulation parameters and the position of the chip
in the eye so that three of the 11 patients were reliably able to recognize
simple patterns when the chip was turned on and even bright objects against a
dark background. In fact, the last test subject correctly recognized letters of
the alphabet that measured ca. 8 cm high, was able to localize people in a
room, and identified their size. A standard visual examination of this patient
with Landolt C Rings resulted in a visual acuity of 1/50, which is slightly
above the threshold of legally defined blindness (according to WHO). This was
conclusive proof that the basic concept of the subretinal implants functions
successfully and can lead to usable visual perception.4
The learning effects that the authors observed were noteworthy: the patients
needed only a few hours to learn how to process visual perceptions that were
new to them. One patient who had been completely blind for the last 15 years
was able to see the letters of the alphabet, and told the investigator that the
letters looked "exactly as I learned them at school." When his name was
presented to him, he immediately recognized a spelling error in it. In
addition, hand-eye coordination was also relearned within a few hours. The
patients were able to localize physical objects precisely and point to them
immediately.
Geometric patterns and physical objects from daily life were recognized,
especially when they had very characteristic forms (such as a banana). They
were also able to distinguish items of tableware (spoons, knives, forks) from
one another.
Now that the pilot study is complete, the implant has become the subject of a
multicentered main study with a larger patient set. The aim of the
investigation is to gain regulatory approval for use as a medical product in
1-2 years.
After
it has been successfully used in retinitis pigmentosa patients, the plan is to
test and apply the visual chip in patients with age-related macula degeneration
(AMD) as well.
Acknowledgements.
This research was supported by the German Federal Ministry of Education and
Research, the Kerstan Foundation, and ProRetina Germany.
References.
1. E Zrenner, "Will Retinal Implants Restore Vision?" Science 295, no.
5597
(February 2002): 1022-1025.
2. HG Graf et al., "High Dynamic Range CMOS Imager Technologies for
Biomedical Applications," IEEE Journal of Solid-State Circuits 44, no. 1
(January 2009): 281-289.
3. E Zrenner, "Restoring Neuroretinal Function: New Potentials, Documenta
Ophthalmologica (2007): 56-59.
4. E Zrenner et al., "Subretinal Electronic Chips Allow Blind Patients to
Read Letters and Combine Them to Words," Proceddings of the Royal Society,
Biological Sciences, online (November 3, 2010): doi:10.1098/rspb.2010.1747.
5. L Rothermel et al., "A CMOS Chip With Active Pixel Array and Specific
Test Features for Subretinal Implantation" IEEE Journal of Solid-State Circuits
44, no. 1 (January 2009): 290-300.
Walter-G. Wrobel, PhD, is president and CEO of Retina Implant AG. Alex
Harscher, PhD, is vice president of operations at the company.
Source URL:
http://www.mddionline.com/article/microchips-eye
----------
To send a message to the list, send any message to blindza@xxxxxxxxxxxxx
----------
To unsubscribe from this list, send a message to blindza-request@xxxxxxxxxxxxx
with 'unsubscribe' in the subject line
---
The 'homepage' for this list is at http://www.blindza.co.za
This email has been scanned for viruses and malware, and automatically archived
by Mimecast SA (Pty) Ltd, an innovator in Software as a Service (SaaS) for
business. Mimecast Unified Email Management ™ (UEM) offers email continuity,
security, archiving and compliance with all current legislation. To find out
more, contact Mimecast.
Other related posts:
